Cognition Therapeutics (NASDAQ:CGTX) Given Buy Rating at Chardan Capital

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “buy” rating restated by equities research analysts at Chardan Capital in a note issued to investors on Wednesday,Benzinga reports. They presently have a $11.00 price objective on the stock.

A number of other equities analysts also recently weighed in on the company. HC Wainwright upped their target price on Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a report on Thursday, December 19th. Brookline Capital Management upgraded Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th. Finally, B. Riley upgraded Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $1.00 to $1.50 in a research note on Thursday, December 19th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $8.30.

Cognition Therapeutics Stock Performance

Shares of CGTX opened at $0.46 on Wednesday. Cognition Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.95. The company has a market cap of $19.04 million, a price-to-earnings ratio of -0.47 and a beta of 0.96. The firm has a fifty day moving average of $0.68 and a 200-day moving average of $0.58.

Hedge Funds Weigh In On Cognition Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CGTX. SG Americas Securities LLC bought a new position in shares of Cognition Therapeutics in the fourth quarter worth $26,000. Virtu Financial LLC purchased a new stake in Cognition Therapeutics during the third quarter valued at about $27,000. Two Sigma Investments LP raised its position in Cognition Therapeutics by 372.2% during the fourth quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after purchasing an additional 42,321 shares in the last quarter. Sigma Planning Corp increased its holdings in shares of Cognition Therapeutics by 14.6% in the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after buying an additional 25,050 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Cognition Therapeutics by 8.9% in the fourth quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock worth $247,000 after buying an additional 28,705 shares during the period. 43.35% of the stock is owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.